Abstract Search

ea0098b8 | Basic Science | NANETS2023

ATRX: a novel predictive biomarker for peptide receptor radionuclide therapy in neuroendocrine tumors

Hammad M. , Lee Z. , Asa S.L. , Aboody K. , Mahipal A. , Bajor D. , Chakrabarti S. , Selfridge J.E. , Ocuin L.M. , Hoehn R.S. , Winter J. , Ammori J. , Hardacre J. , Tirumani S.H. , Henke L.E. , Mohamed A.

Background: Peptide receptor radionuclide therapy (PRRT) including Lutetium177 (Lu177) has changed the treatment landscape of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). There is a subgroup of patients who are resistant or develop resistance after initial success to PRRT, indicating that accurate predictive markers are urgently needed to identify who will benefit from PRRT. We hypothesize that expression of ATRX (Alpha Thalassemia and Mental Retardation...

0 shares

ea0098c6 | Clinical – Chemo/SSA/Biologics | NANETS2023

The role of somatostatin analogue maintenance therapy in refractory metastatic neuroendocrine tumors (NETs): comparative analysis

Mohamed A. , Kurian M. , Patil S. , Asa S.L. , Tirumani S.H. , Mahipal A. , Bajor D. , Chakrabarti S. , Selfridge J.E. , Ocuin L.M. , Hoehn R.S. , Winter J. , Ammori J. , Hardacre J. , Henke L.E. , Bahar L.

Background: Somatostatin analogues (SSAs) are the standard of care first line therapy for metastatic well-differentiated neuroendocrine tumors (NETs). They are approved for both alleviating hormone-related symptoms for functional tumors and inhibiting tumor growth. Their anti-proliferative benefit in the refractory setting is debatable due to lack of supportive literature. This systematic review compared efficacy of targeted therapies (Everolimus, Sunitinib, Surufatinib, Lenva...

0 shares

Endocrine Abstracts

ATRX: a novel predictive biomarker for peptide receptor radionuclide therapy in neuroendocrine tumors

The role of somatostatin analogue maintenance therapy in refractory metastatic neuroendocrine tumors (NETs): comparative analysis

BiosciAbstracts